Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutation status for patients with nonsquamous NSCLC in Italy, Spain, Germany, and Australia.</p
The availability of targeted drugs has made the assessment of the EGFR mutation and ALK rearrangemen...
Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGF...
Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC...
Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutatio...
EGFR mutation analysis in non-small-cell lung cancer (NSCLC) patients is currently standard-of-care....
In order to improve outcomes, identification of the epidermal growth factor receptor (EGFR) and anap...
ESMO consensus recommends EGFR mutation testing in never/former light smokers (<15 pack-years) or pa...
EGFR mutation analysis in non-small-cell lung cancer (NSCLC) patients is currently standard-of-care....
<p>EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.</p
Kaplan-Meier plots of overall survival from initiation of first- and second-line therapy by predicti...
The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC) targetable ...
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor...
Treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung canc...
<p>(A) <i>EGFR</i> mutation status across all NSCLC samples is shown. Black segment in the inner cir...
The availability of targeted drugs has made the assessment of the EGFR mutation and ALK rearrangemen...
Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGF...
Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC...
Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutatio...
EGFR mutation analysis in non-small-cell lung cancer (NSCLC) patients is currently standard-of-care....
In order to improve outcomes, identification of the epidermal growth factor receptor (EGFR) and anap...
ESMO consensus recommends EGFR mutation testing in never/former light smokers (<15 pack-years) or pa...
EGFR mutation analysis in non-small-cell lung cancer (NSCLC) patients is currently standard-of-care....
<p>EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.</p
Kaplan-Meier plots of overall survival from initiation of first- and second-line therapy by predicti...
The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC) targetable ...
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor...
Treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung canc...
<p>(A) <i>EGFR</i> mutation status across all NSCLC samples is shown. Black segment in the inner cir...
The availability of targeted drugs has made the assessment of the EGFR mutation and ALK rearrangemen...
Introduction: Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend EGF...
Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC...